CN113101310B

CN113101310B - Medicine for preventing and/or treating coronavirus infection and preparation method thereof

Info

Publication number: CN113101310B
Application number: CN202110327456.9A
Authority: CN
Inventors: 詹华强; 董婷霞; 梁嘉荣; 段然; 邓伟麟; 李芷晴; 林彤姿; 司徒嘉珈
Original assignee: Hong Kong University of Science and Technology HKUST
Current assignee: Hong Kong University of Science and Technology HKUST
Priority date: 2021-03-26
Filing date: 2021-03-26
Publication date: 2022-09-23
Anticipated expiration: 2041-03-26
Also published as: CN113101310A

Abstract

The invention relates to a medicament for preventing or/and treating coronavirus infection and a preparation method thereof. The inventor finds that the commonly used Lingnan medicinal materials including Chinese knotweed, emblic leafflower fruit, bitter orange, roughhaired holly root, desmodium, climbing fern vine, cattle tea, desmodium, loquat leaf and hypericum japonicum can reduce the spike protein of coronavirus and reduce the combination of the spike protein and angiotensin converting enzyme 2, thereby playing a role in inhibiting coronavirus. Based on the discovery, the medicinal materials and the traditional Chinese medicine composition containing the medicinal materials are used for preparing the medicine for preventing or/and treating the coronavirus infection, and a new solution is provided for controlling the coronavirus infection.

Description

Medicine for preventing and/or treating coronavirus infection and preparation method thereof

Technical Field

The invention belongs to the field of biomedicine, relates to a traditional Chinese medicine composition, and particularly relates to a medicine for preventing or/and treating coronavirus infection and a preparation method thereof.

Background

Coronaviruses are a large family of viruses known to cause more severe diseases such as the common cold, Middle East Respiratory Syndrome (MERS), and Severe Acute Respiratory Syndrome (SARS). The novel coronavirus is a new strain of coronavirus that has not been previously found in humans. The international committee for virus classification has named this new pathogen severe acute respiratory syndrome coronavirus No. 2 (segment acid respiratory syndrome coronavirus 2) or SARS-CoV-2, which is referred to as "new coronavirus" for short in the present invention.

After a person is infected with a new coronavirus (SARS-CoV-2), the common signs of the person include respiratory symptoms, fever, cough, shortness of breath, dyspnea and the like. In more severe cases, the infection can lead to pneumonia, severe acute respiratory syndrome, renal failure, and even death. At present, no specific treatment method exists for diseases caused by the new coronavirus, no antiviral drug specifically aiming at the new coronavirus exists, and the vaccine cannot be widely inoculated.

The traditional Chinese medicine is a treasure left by ancestors for us for thousands of years, is used for preventing and treating diseases and has the functions of rehabilitation and health care, and particularly serves as a minister of epidemic prevention. The habit of inserting folium artemisiae argyi and wearing a fragrant bag at noon has been existed since ancient times, and the fragrant bag has the functions of resuscitation, dirt avoidance and epidemic avoidance. However, there are few kinds of drugs currently used for preventing or/and treating coronavirus, and the choice of the kinds of the epidemic prevention drugs is greatly limited. Therefore, there is a need to develop a candidate drug for inhibiting the new coronavirus.

Disclosure of Invention

Based on the above, the main object of the present invention is to provide a medicament for preventing or/and treating coronavirus infection and a preparation method thereof. The medicine provided by the invention can obviously inhibit coronavirus, and provides a new solution for preventing or/and treating coronavirus infection.

The technical scheme of the invention comprises the following steps:

the application of the cissampelos mutica, the goldenrod tea or/and the desmodium triquetrum in preparing the medicine for preventing or/and treating coronavirus infection.

In one embodiment, the coronavirus is severe acute respiratory syndrome coronavirus No. 2, severe acute respiratory syndrome coronavirus, middle east respiratory syndrome coronavirus, or batsars-like coronavirus.

A medicine for preventing and/or treating coronavirus infection comprises caulis Sargentodoxae, herba Tagetis Erectae or/and herba Desmodii Triquetri, and at least one of herb Polygoni chinensis, fructus Phyllanthi, thin Evodia, radix Ilicis Asprellae, herba Lysimachiae Christinae, folium Eriobotryae, herba Hyperici Japonici and herba Houttuyniae.

In one embodiment, the medicine comprises lygodium japonicum stem, goldenrod, desmodium triquetrum, loquat leaf and hypericum japonicum.

In one embodiment, the medicine comprises, by mass, 1 to 15 parts of lygodium japonicum, 1 to 15 parts of cattle tea, 1 to 15 parts of desmodium triquetrum, 1 to 15 parts of loquat leaves and 1 to 15 parts of hypericum japonicum.

In one embodiment, the medicine comprises lygodium japonicum, goldenrod, desmodium, emblic leafflower fruit, thin evodia leaf, roughhaired holly root, desmodium, loquat leaf and hypericum japonicum.

In one embodiment, the medicine comprises, by mass, 1 to 15 parts of Chinese knotweed, 1 to 15 parts of emblic leafflower fruit, 1 to 15 parts of bitter orange, 1 to 15 parts of roughhaired holly root and 1 to 15 parts of desmodium.

In one embodiment, the medicine comprises lygodium japonicum, goldenrod, desmodium triquetrum, winter mulberry leaf, honeysuckle stem, sticktight, houttuynia, achyranthes aspera, loquat leaf, mandarin orange, wild chrysanthemum, white paper fan, picea javanica, hypericum japonicum, microcos paniculata, thin evodia, desmodium, lophatherum gracile, emblic leafflower fruit, roughhaired holly root, lindera communis leaf, wild sesame, dandelion and herb of Chinese knotweed.

In one embodiment, the medicine comprises, by mass, 1 to 3 parts of lygodium japonicum, 1 to 3 parts of cattle bezoar tea, 1 to 3 parts of desmodium triquetrum, 1 to 3 parts of folium mori, 1 to 3 parts of silvervine, 1 to 3 parts of sticktight, 1 to 3 parts of houttuynia cordata, 1 to 3 parts of achyranthes aspera, 1 to 3 parts of loquat leaves, 1 to 3 parts of caper, 1 to 3 parts of wild chrysanthemum flower, 1 to 3 parts of white paper fan, 1 to 3 parts of schefflera octophylla, 1 to 3 parts of hypericum japonicum, 1 to 3 parts of microcos paniculata, 1 to 3 parts of trifoliate bitter, 1 to 3 parts of desmodium, 1 to 3 parts of lophatherum gracile, 1 to 3 parts of emblic leafflower, 1 to 3 parts of roughhaired holly root, 1 to 3 parts of woodchuck, 1 to 3 parts of sesame, 1 to 3 parts of dandelion, and 1 to 3 parts of Chinese knotweed.

In one embodiment, the dosage form of the medicine is decoction, granules, tablets or capsules.

The preparation method of the medicament for preventing or/and treating coronavirus infection comprises the following steps: decocting the above materials with water, and collecting medicinal liquid.

In one embodiment, the mass of the water is 10-15 times of the mass of the medicinal materials, the decocting times are 1-3 times, and the time length of each decocting is 0.8-1.2 hours.

In one embodiment, the preparation method further comprises the step of preparing the liquid medicine into decoction, granules, tablets or capsules.

Use of thin evodia leaf or/and herb Polygoni chinensis in preparing medicine for preventing and/or treating coronavirus infection is provided.

A medicine for preventing and/or treating coronavirus infection comprises evodia lepta, Chinese knotweed, desmodium, emblic leafflower fruit and roughhaired holly root.

In one embodiment, the medicine comprises 1 to 15 parts of evodia lepta, 1 to 15 parts of Chinese knotweed herb, 1 to 15 parts of desmodium, 1 to 15 parts of emblic leafflower fruit and 1 to 15 parts of roughhaired holly root by mass.

In one embodiment, the mass of the water is 10-15 times of that of the medicinal materials, the decocting times are 1-3 times, and the time length of each decocting is 0.8-1.2 hours.

In one embodiment, the preparation method further comprises the step of preparing the liquid medicine into decoction, tablets or capsules.

Compared with the prior art, the invention has the following beneficial effects:

in the research process, the inventor finds that the common Lingnan medicinal materials (including Chinese knotweed herb, emblic leafflower fruit, bitter orange, roughhaired holly root, desmodium, Japanese climbing fern vine, cattle tea, desmodium, loquat leaf and hypericum japonicum) can reduce the spike protein of coronavirus, reduce the combination of the spike protein and angiotensin converting enzyme 2(ACE2), and thus can play a role in inhibiting the coronavirus. Based on the discovery, the medicinal materials and the traditional Chinese medicine composition containing the medicinal materials are used for preparing the medicine for preventing or/and treating the coronavirus infection, and a new solution is provided for controlling the coronavirus infection.

Drawings

FIG. 1 is a graph showing the results of anti-coronavirus effect of aqueous herbal extracts (1% by weight/volume) according to some embodiments of the present invention;

FIG. 2 is a graph showing the results of anti-coronavirus effect of aqueous extracts of Chinese medicinal formulation A at different concentrations (0.03%, 0.1%, 0.3%, 1%, 3% by mass/volume) according to some embodiments of the present invention;

FIG. 3 is a graph showing the results of anti-coronavirus effects of various concentrations of aqueous traditional Chinese medicine formulation B extracts (0.03%, 0.1%, 0.3%, 1%, 3% by mass/volume) according to some embodiments of the present invention;

figure 4 is a graphical representation of the results of anti-coronavirus effects of different concentrations of aqueous traditional Chinese medicine formulation C extracts (0.03%, 0.1%, 0.3%, 1%, 3% by mass/volume) according to some embodiments of the present invention.

Detailed Description

In order that the invention may be more fully understood, reference will now be made to the following description. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used herein, the term "and/or" includes any and all combinations of one or more of the associated listed items.

Lingnan medicinal materials are widely used traditional Chinese medicines in Guangdong, Guangxi, Fujian and the like, and most of the Lingnan medicinal materials are recorded in Chinese pharmacopoeia, wherein Guangdong herbal tea is listed as a first national-grade non-material culture heritage list in 2006.

The embodiment of the invention screens the commonly used Lingnan medicinal materials against the new coronavirus (SARS-CoV-2), finds the medicinal materials capable of resisting the new coronavirus (SARS-CoV-2) and further recombines the medicinal materials. In the research process, common Lingnan medicinal materials (including Chinese knotweed herb, emblic leafflower fruit, bitter orange, roughhaired holly root, desmodium, Japanese climbing fern vine, cattle tea, desmodium triquetrum, loquat leaf, hypericum japonicum and the like) can obviously reduce the spike protein of coronavirus, reduce the combination of the spike protein and angiotensin converting enzyme 2(ACE2), and thus can play a role in inhibiting coronavirus. Based on the discovery, the Lingnan medicinal materials and the composition containing the Lingnan medicinal materials are used for preparing the medicines for preventing or/and treating the coronavirus infection, and a new solution is provided for controlling the coronavirus infection.

The Lingnan medicinal materials related to the embodiment of the invention comprise:

charcoal mother: is dried whole plant of Polygonaceae plant Polygoni chinensis (Polygonum chinense L.). Slightly sour and astringent taste and cool nature. Has the functions of clearing away heat and toxic material, eliminating dampness, eliminating stagnation, cooling blood, relieving itching, improving eyesight and eliminating nebula. Can be used for treating dysentery, dyspepsia, hepatitis, common cold, tonsillitis, pharyngolaryngitis, diphtheria, pertussis, corneal nebula, mastitis, mycotic vaginitis, leucorrhea, furuncle, infantile pustule, eczema, and venomous snake bite.

Emblic leafflower fruit: is fruit of Phyllanthus emblica L (Phyllanthus emblica L.) belonging to Phyllanthus of Euphorbiaceae. Sweet, sour, astringent and cool in nature. Has the effects of clearing heat and cooling blood, promoting digestion and invigorating stomach, and promoting the production of body fluid and relieving cough. Can be used for treating blood heat and blood stasis, dyspepsia, abdominal distention, cough, laryngalgia, and xerostomia.

Bitter taste in trifacial: is root, branch and leaf of Evodia rutaecarpa (Evodia lepta (Spreng.) Merr.) of Rutaceae. Slightly bitter taste and cold nature. Has the effects of clearing away heat and toxic materials, dispelling pathogenic wind and removing dampness. Can be used for treating swelling and pain of throat, rheumatalgia, malaria, jaundice, eczema, dermatitis, traumatic injury, insect bite, and snake bite.

Roughhaired holly root: is root or stem of Ilex asprella (hook. et Am.) champ. ex Benth) belonging to family Aquifoliaceae. Bitter and sweet in taste, cold in nature. Has the functions of clearing away heat and toxic material, promoting the production of body fluid and quenching thirst. Can be used for treating common cold, hyperpyrexia, polydipsia, tonsillitis, pharyngolaryngitis, tracheitis, pertussis, diarrhea, dysentery, infectious hepatitis, wild mushroom, and arsenicum poisoning.

Herba Lysimachiae Christinae: is fresh or dried whole plant of primula family plant of Lysimachia christinae Hance or aerial part of Desmodium styracifolium (Osh.) Merr.) of Leguminosae family. Or sweet and bland in flavor and slightly cold in nature. Has the effects of removing dampness and jaundice, promoting urination and treating stranguria, and removing toxic substance and detumescence, and can be used for treating damp-heat jaundice.

Loquat leaf: is leaf of Eriobotrya japonica (Thunb.) Lindl.) belonging to family Rosaceae, genus Eriobotrya. Bitter and slightly pungent in flavor, slightly cold in nature. Has the effects of clearing away lung-heat, relieving cough, regulating stomach, lowering adverse qi, and quenching thirst.

And (3) golden sargentgloryvine stem: is rattan stem and spore-bearing leaf of Lygodium japonicum (Thunb.) Sw of the family Hypsizygus marmoreus. Sweet in flavor and cold in nature. Has the effects of clearing away heat and toxic materials, promoting diuresis and treating stranguria.

Herba Hyperici Japonici: is whole grass of Hypericum japonicum Thunb. Sweet and bitter in taste and cool in nature. Has the effects of clearing away heat and toxic materials, promoting diuresis, removing blood stasis, and relieving swelling.

And (3) yellow cattle tea: is root, bark or tender leaf of Cratoxylum cochinchenense (Lour.) Bl.) of family Guttiferae. Sweet, slightly bitter and cool in nature. Relieve summer-heat, clear heat, promote diuresis and remove food stagnation. Can be used for treating common cold, heatstroke, fever, acute gastroenteritis, and jaundice.

Calabash tea: is aerial part of Cucurbita pepo L (L.) Ohashi of Leguminosae. Bitter and astringent taste, and cool in nature. Has the effects of clearing away heat and toxic materials, promoting diuresis, removing jaundice, removing food retention, and killing parasites.

The embodiment of the invention discovers new application of Lingnan medicinal materials including sargentgloryvine stem, cattle tea and desmodium triquetrum, namely application of the sargentgloryvine stem, the cattle tea or/and the desmodium triquetrum in preparation of a medicament for preventing or/and treating coronavirus infection. The embodiment of the invention discovers that single Chinese medicinal materials of sargentgloryvine stem, goldenrod tea and desmodium triquetrum can have the effect of resisting coronavirus infection, based on the discovery, the three Chinese medicinal materials can be respectively prepared into the medicaments for preventing or/and treating the coronavirus infection, two or three of the Chinese medicinal materials can be combined to prepare the medicaments for preventing or/and treating the coronavirus infection, or at least one of the three Chinese medicinal materials is compatible with other Chinese medicinal materials to prepare the medicaments for preventing or/and treating the coronavirus infection.

The 'medicine' described in the embodiment of the invention refers to a substance which is used for prevention or/and treatment and has the effects of rehabilitation and health care under the guidance of the theory of traditional Chinese medicine, and the substance can be a substance which needs to be used under the guidance of a doctor or a substance which can be used without the guidance of the doctor (such as herbal tea).

The embodiment of the invention provides a medicine for preventing or/and treating coronavirus infection, which comprises lygodium japonicum, goldenrod tea or/and desmodium triquetrum, and at least one of Chinese knotweed herb, emblic leafflower fruit, trifoliate bitter orange, roughhaired holly root, desmodium, loquat leaf, hypericum japonicum and houttuynia cordata.

In one example, the medicine comprises lygodium japonicum stem, goldenrod, desmodium triquetrum, loquat leaf, and hypericum japonicum.

In one example, the medicine comprises, by mass, 1 to 15 parts of lygodium japonicum, 1 to 15 parts of cattle tea, 1 to 15 parts of desmodium triquetrum, 1 to 15 parts of loquat leaves, and 1 to 15 parts of hypericum japonicum. The drug described in the embodiment of the present invention may be an extract of these herbs, for example, the extract may be an extract with a crude drug concentration of 0.3% to 3.0%, preferably an extract with a crude drug concentration of 1.0% to 3.0%, and more preferably an extract with a crude drug concentration of 3.0%. Further preferably, the medicine comprises, by mass, 5 to 15 parts of lygodium japonicum, 5 to 15 parts of cattle tea, 5 to 15 parts of desmodium triquetrum, 5 to 15 parts of loquat leaves and 5 to 15 parts of hypericum japonicum.

In one example, the medicament comprises lygodium japonicum, goldenrod, desmodium triquetrum, phyllanthus emblica, evodia lepta, roughhaired holly root, desmodium, loquat leaf, and hypericum japonicum.

In one example, the medicine comprises, by mass, 1 to 15 parts of lygodium japonicum, 1 to 15 parts of cattle tea, 1 to 15 parts of desmodium triquetrum, 1 to 15 parts of polygonum chinense, 1 to 15 parts of emblic leafflower fruit, 1 to 15 parts of trifoliate bitter herb, 1 to 15 parts of roughhaired holly root, 1 to 15 parts of longhairy antenoron herb, 1 to 15 parts of loquat leaf and 1 to 15 parts of hypericum japonicum. The drug described in the embodiment of the present invention may be an extract of these herbs, for example, the drug concentration may be 0.1% to 3.0%, preferably 0.3% to 3.0%, more preferably 1.0% to 3.0%, and still more preferably 3.0%. Further preferably, the medicine comprises 5 to 15 parts of lygodium japonicum, 5 to 15 parts of Huangniu tea, 5 to 15 parts of desmodium triquetrum, 5 to 15 parts of phyllanthus emblica, 5 to 15 parts of trifoliate bitter orange, 5 to 15 parts of roughhaired holly root, 5 to 15 parts of longhairy antenoron herb, 5 to 15 parts of loquat leaf and 5 to 15 parts of hypericum japonicum.

In one example, the medicament comprises lygodium japonicum, goldenrod, desmodium triquetrum, winter mulberry leaf, honeysuckle stem, sticktight, houttuynia, achyranthes aspera, loquat leaf, mandarin orange, wild chrysanthemum, white paper fan, picea javanica, hypericum japonicum, microcos paniculata, desmodium, lophatherum gracile, emblic leafflower fruit, roughhaired holly root, tabasheer, screwtree root, dandelion and herb of Chinese knotweed.

In one example, the medicine comprises, by mass, 1 to 3 parts of lygodium japonicum, 1 to 3 parts of cattle tea, 1 to 3 parts of cucurbit tea, 1 to 3 parts of winter mulberry leaf, 1 to 3 parts of honeysuckle stem, 1 to 3 parts of sticktight, 1 to 3 parts of houttuynia cordata, 1 to 3 parts of achyranthes aspera, 1 to 3 parts of loquat leaf, 1 to 3 parts of citrus changium, 1 to 3 parts of wild chrysanthemum, 1 to 3 parts of white paper fan, 1 to 3 parts of schefflera arboricola, 1 to 3 parts of hypericum japonicum, 1 to 3 parts of microcos paniculata, 1 to 3 parts of trifoliate, 1 to 3 parts of desmodium, 1 to 3 parts of lophatherum gracile, 1 to 3 parts of emblic leafflower fruit, 1 to 3 parts of roughhaired holly root, 1 to 3 parts of morinda officinalis wood, 1 to 3 parts of sesame, 1 to 3 parts of dandelion, and 1 to 3 parts of Chinese knotweed herb. The drug described in the embodiment of the present invention may be an extract of these herbs, for example, the drug concentration may be 0.1% to 3.0%, preferably 0.3% to 3.0%, more preferably 1.0% to 3.0%, and still more preferably 3.0%.

The embodiment of the invention also relates to a preparation method of the medicine for preventing or/and treating coronavirus infection, which comprises the following steps: decocting the above materials with water, and collecting medicinal liquid.

In one example, the mass of the water is 10-15 times of the mass of the medicinal materials, the decocting times are 1-3 times, and the time length of each decocting is 0.8-1.2 hours. For example, 12 times of water is added to the medicinal materials, and the mixture is decocted for 2 times, 1 hour each time.

In one example, the preparation method further comprises the step of preparing the liquid medicine into decoction, granules, tablets or capsules.

The embodiment of the invention relates to application of thin evodia and/or leonurus in preparation of a medicine for preventing or/and treating coronavirus infection.

A medicine for preventing or/and treating coronavirus infection comprises thin evodia, Chinese knotweed, desmodium, emblic leafflower fruit and roughhaired holly root.

In one example, the medicine comprises 1 to 15 parts of bitter orange, 1 to 15 parts of Chinese knotweed herb, 1 to 15 parts of desmodium, 1 to 15 parts of emblic leafflower fruit and 1 to 15 parts of roughhaired holly root by mass. The drug described in the embodiment of the present invention may be an extract of these medicinal materials, and for example, may be an extract having a crude drug concentration of 0.03% to 3.0%, preferably an extract having a crude drug concentration of 0.1% to 3.0%, preferably an extract having a crude drug concentration of 0.3% to 3.0%, more preferably an extract having a crude drug concentration of 1.0% to 3.0%, and still more preferably 3.0%. Further preferably, the medicine comprises, by mass, 5 to 15 parts of bitter orange, 5 to 10 parts of Chinese knotweed, 2.5 to 10 parts of desmodium, 2.5 to 10 parts of emblic leafflower fruit and 2.5 to 10 parts of roughhaired holly root.

The embodiment of the invention relates to a preparation method of the medicine for preventing or/and treating coronavirus infection, which comprises the following steps: decocting the above materials with water, and collecting medicinal liquid.

In one example, the mass of the water is 10-15 times of the mass of the medicinal materials, the decocting times are 1-3 times, and the time length of each decocting is 0.8-1.2 hours. For example, 12 times of water is added to the medicinal materials, and the mixture is decocted for 2 times, 1 hour each time. In one example, the preparation method further comprises the step of preparing the liquid medicine into decoction, granules, tablets or capsules.

The dosage form of the medicament is not particularly limited in the embodiment of the invention, and can be any suitable dosage form, such as decoction, granules, tablets, capsules and the like. It can be understood that, in the process of making the liquid medicine into a certain dosage form according to the requirement of the dosage form, a suitable pharmaceutical excipient may be added, and the types of the pharmaceutical excipient described in the embodiments of the present invention include, but are not limited to, a carrier, a dispersant, and the like.

The "coronavirus" referred to in the embodiments of the present invention includes, but is not limited to, severe acute respiratory syndrome coronavirus No. 2 (SARS-CoV-2), severe acute respiratory syndrome coronavirus (SARS-CoV), middle east respiratory syndrome coronavirus (MERS-CoV), or Bat SARS-like coronavirus (bat-SL-CoVZC45), etc.

Example 1 aqueous extract of Single Chinese medicinal materials

Respectively preparing a winter mulberry leaf water extract, a honeysuckle stem water extract, a sticktight water extract, a houttuynia cordata water extract, a achyranthes aspera water extract, a loquat leaf water extract, a mandarin orange water extract, a wild chrysanthemum water extract, a white paper fan water extract, a climbing fern water extract, a schefflera arboricola water extract, a hypericum japonicum water extract, a microcosmic water extract, a lysimachia christinae water extract, a lophatherum gracile water extract, an emblic leafflower water extract, a roughhaired holly root water extract, a cattle tea water extract, a cornutus chinensis water extract, a screwtree root water extract, a calabash tea water extract, a dandelion water extract and a Chinese knotweed herb mother water extract.

The preparation method of the aqueous extract comprises the following steps:

(1) soaking the medicinal materials in 12 times of water for half an hour, heating and decocting for 1 hour, separating residue, and filtering to obtain medicinal liquid;

(2) adding the same amount of water (12 times of the medicinal materials) into the residue, heating and decocting for 1 hr, separating the residue, and filtering to obtain medicinal liquid.

(3) And (3) combining the liquid medicines obtained in the step (1) and the step (2).

Example 2 Chinese medicine formula A

(1) Weighing the raw materials according to the proportion listed in Table 1, adding 12 times of water by mass, soaking for half an hour, heating and boiling for 1 hour, separating medicine residues, and filtering out medicine liquid.

(3) Mixing the medicinal solutions.

(4) And (3) extracting 25mL of liquid medicine to a 50mL centrifuge tube, placing the centrifuge tube in a refrigerator at the temperature of-80 ℃ for 24 hours, transferring the centrifuge tube to a freeze dryer, and freeze-drying the centrifuge tube for 1 week until all the liquid medicine is dried into powder.

TABLE 1

Example 3 Chinese medicine formula B

(1) Weighing the raw materials according to the proportion listed in Table 2, adding 12 times of water by mass, soaking for half an hour, heating and cooking for 1 hour, separating dregs, and filtering out the liquid medicine.

(3) Mixing the medicinal solutions.

(4) And (3) extracting 25mL of liquid medicine to a 50mL centrifuge tube, placing the centrifuge tube in a refrigerator at the temperature of 80 ℃ below zero for 24 hours, moving the centrifuge tube to a freeze dryer, and freeze-drying the centrifuge tube for 1 week until all the liquid medicine is dried into powder.

TABLE 2

Numbering	Medicinal materials	Parts by mass (g)
			6	Folium Eriobotryae	10g
10	Caulis et folium Hedyotis Hedyotideae	10g
			12	Hypericum japonicum Thunb	10g
19	Huangniu tea	10g
			22	Calabash tea	10g

Example 4 Chinese medicine formula C

(1) Weighing the raw materials according to the proportion listed in Table 3, adding 12 times of water by mass, soaking for half an hour, heating and boiling for 1 hour, separating medicine residues, and filtering out medicine liquid.

(2) Adding the same amount of water (12 times of the weight of Lingnan medicinal materials) into the residue, decocting for 1 hr, separating the residue, and filtering to obtain medicinal liquid.

(3) Mixing the medicinal solutions.

TABLE 3

Efficacy test, study of anti-New coronavirus (SARS-CoV-2)

The first, experimental principle: the antiviral effect of the Chinese medicinal extract is shown by detecting the inhibition effect of the medicinal extract sample on Spike protein (Spike protein) existing in the shell of the new coronavirus (SARS-CoV-2). When the spike protein is inhibited by herbal extracts, its binding to the human receptor angiotensin-converting enzyme 2(ACE2) is reduced. The less the spike protein binds to ACE2, the stronger the Chinese medicinal extract has the effect of inhibiting the spike protein. The method is an effective in vitro detection means for testing the efficacy of the medicine for resisting the new coronavirus (SARS-CoV-2).

II, experimental materials:

(1) an aqueous extract of winter mulberry leaves, an aqueous extract of honeysuckle flowers, an aqueous extract of sticktight, an aqueous extract of houttuynia cordata, an aqueous extract of achyranthes aspera, an aqueous extract of loquat leaves, an aqueous extract of mandarin orange, an aqueous extract of wild chrysanthemum, an aqueous extract of white paper, an aqueous extract of lygodium japonicum, an aqueous extract of dittany, an aqueous extract of hypericum japonicum, an aqueous extract of microcos paniculata, an aqueous extract of desmodium, an aqueous extract of lophatherum gracile, an aqueous extract of emblic leafflower fruit, an aqueous extract of roughhaired holly root, an aqueous extract of cattle tea, an aqueous extract of woodlouse leaves, an aqueous extract of screwtree flower seeds, an aqueous extract of cucurbit tea, an aqueous extract of dandelion, and an aqueous extract of Chinese knotweed herb prepared in example 1.

(2) The traditional Chinese medicine prepared in example 2 is formula a.

(3) The traditional Chinese medicine formula B prepared in example 3.

(4) The traditional Chinese medicine prepared in example 4 is formula C.

(5) A positive control was defined by a 5% aqueous DMSO solution and a solution without ACE2-His, and a negative control was defined by a 5% aqueous DMSO solution and a solution with ACE2-His at a concentration of 2.5 ng/. mu.L. SARS-CoV-2 Spike, ACE2 Inhibitor Screening Assay Kit, from BPS Bioscience.

Thirdly, experimental steps:

the spike protein solution at a concentration of 1. mu.g/mL was added to a specially prepared 96-well plate at 50. mu.L per well and incubated overnight at 4 ℃.

After incubation was complete, the supernatant was decanted and washed 3 times with 100 μ L of blocking solution a.

The solution was patted dry, 100. mu.L of blocking solution B was added to each well, and the mixture was shaken at room temperature for 1 hour.

After the solution was patted dry, 20. mu.L of blocking solution A was added to each well, 10. mu.L of 5% DMSO aqueous solution was added to each of the positive control well and the negative control well, 10. mu.L of sample solution (containing 5% DMSO) was added to each of the sample wells, and the mixture was shaken at room temperature for 1 hour.

20 mu L of confining liquid A is added into the positive control hole, the situation of the highest inhibition rate of the simulation experiment is taken as the positive control by adding the confining liquid A without ACE2-His, 20 mu L of ACE2-His solution with the concentration of 2.5 ng/mu L is respectively added into the negative control hole and the sample hole, and the reaction is carried out for 1 hour under the oscillation at room temperature.

After completion of the reaction, the liquid was patted dry and washed 3 times with 100. mu.L of blocking solution A. The solution was patted dry, 100. mu.L of blocking solution B was added to each well, and the mixture was incubated at room temperature for 10 minutes.

After the incubation, the liquid was patted dry, 10. mu.L of Anti-His-HRP solution was added to each well, and the mixture was incubated at room temperature with shaking for 1 hour.

The cells were washed 3 times with 100. mu.L of blocking solution A, and then 100. mu.L of blocking solution B was added to each well, followed by incubation at room temperature for 10 minutes.

Finally, the liquid was patted dry and a mixture of 100. mu. L ELISA ECL substrate A and B (1:1) was added to each well to measure the intensity of chemiluminescence.

Fourthly, experimental results:

as shown in figure 1, 10 of 24 single Chinese medicinal aqueous extracts (1 percent by mass and volume) of loquat leaf, Japanese climbing fern vine, hypericum japonicum, cattle tea, calabash tea, herb of Chinese knotweed, emblic leafflower fruit, trifoliate orange, roughhaired holly root and longhairy antenoron herb have remarkable anti-new crown virus (SARS-CoV-2) effect.

TABLE 4

As shown in fig. 2, 3 and 4: the Chinese medicine formula A, the Chinese medicine formula B and the Chinese medicine formula C can effectively inhibit S protein at the concentration of 1 percent and 3 percent to play a role in resisting coronavirus. At a concentration of 0.3%, the Chinese medicinal formula B cannot inhibit the protein S by only about 40% of the Chinese medicinal formula A, and the Chinese medicinal formula C has about 90% of the inhibition. At a concentration of 0.1%, neither formula A nor formula B has S protein inhibitory effect, and formula C has about 40% inhibitory effect. At the concentration of 0.03%, the traditional Chinese medicine formula A, the traditional Chinese medicine formula B and the traditional Chinese medicine formula C have no S protein inhibition effect.

The inhibition of the traditional Chinese medicine formula A, the traditional Chinese medicine formula B and the traditional Chinese medicine formula C on coronavirus under various concentrations is shown in the following table.

TABLE 5

	Traditional Chinese medicine formula A	Traditional Chinese medicine formula B	Traditional Chinese medicine formula C
				Positive control	100％	100％	100％
Negative control	0％	0％	0％
				0.03％	-45.5％	-28.8％	1.5％
0.1％	-27.3％	-21.2％	33.4％
				0.3％	37.9	-1.5％	85.8％
1％	81.8％	63.7％	99.3％
				3％	98.8％	97.4％	99.8％

In the 3 combinations, the traditional Chinese medicine formula C (Chinese knotweed, emblic leafflower fruit, bitter orange, roughhaired holly root and desmodium) has good S protein inhibition effect at the concentration of more than 0.03 percent, and is superior to the traditional Chinese medicine formula A and the traditional Chinese medicine formula B.

Examples 5 to 6

Examples 5 and 6 are modifications of example 2, which are based on the amount of the herbs used in example 2, and the specific formula is shown in Table 6.

Examples 7 to 8

Example 7 and example 8 are modifications of example 3, which are based on the amount of the herbs used in example 3, and the specific formula is shown in Table 6.

Examples 9 to 10

Example 9 and example 10 are modifications of example 4, which are based on the amount of the herbs used in example 4, and the specific formula is shown in Table 6.

Examples 11 to 12

Example 11 and example 12 provide a traditional Chinese medicine formula D comprising 10 kinds of medicinal materials, respectively, including: loquat leaves, golden sargentgloryvine stems, hypericum japonicum, cattle tea, calabash tea, Chinese knotweed herbs, phyllanthus emblica, thin evodia herbs, roughhaired holly roots and longhairy antenoron herbs. The Chinese medicinal formula provided in example 11 and example 12 is specifically shown in table 6 in parts by mass.

TABLE 6

The anti-neocoronaviral effects of the Chinese medicinal formulations provided in examples 5 to 12 were tested with reference to the above efficacy tests, and the results are shown in Table 7 below.

TABLE 7

The technical features of the embodiments described above may be arbitrarily combined, and for the sake of brevity, all possible combinations of the technical features in the embodiments described above are not described, but should be considered as being within the scope of the present specification as long as there is no contradiction between the combinations of the technical features.

The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.

Claims

1. The medicine for preventing or/and treating coronavirus infection is characterized by consisting of 1-15 parts of honeysuckle sargentgloryvine stem, 1-15 parts of cattle tea, 1-15 parts of desmodium triquetrum, 1-15 parts of loquat leaf and 1-15 parts of hypericum japonicum;

the coronavirus is new coronavirus SARS-CoV-2.

2. The medicament for preventing or/and treating coronavirus infection according to claim 1, wherein the medicament is in the form of decoction, granules, tablets or capsules.

3. The process for the preparation of a medicament for the prevention or/and treatment of coronavirus infection according to claim 1 or 2, wherein the process for the preparation comprises the steps of: decocting the above materials with water, collecting medicinal liquid, and lyophilizing.

4. The method for preparing a medicament for preventing or/and treating coronavirus infection according to claim 3, wherein the mass of the water is 10-15 times of the mass of the medicinal materials, the decocting times are 1-3 times, and the time length of each decocting is 0.8-1.2 hours.

5. The medicine for preventing or/and treating coronavirus infection is characterized by consisting of 1-15 parts of thin evodia, 1-15 parts of Chinese knotweed herb, 1-15 parts of desmodium, 1-15 parts of emblic leafflower fruit and 1-15 parts of roughhaired holly root by mass;

the coronavirus is new coronavirus SARS-CoV-2.

6. The medicament for preventing or/and treating coronavirus infection according to claim 5, wherein the medicament is in the form of decoction, granules, tablets or capsules.

7. The method for preparing a medicament for preventing or/and treating coronavirus infection according to claim 5 or 6, wherein the preparation method comprises the following steps: decocting the above materials with water, collecting medicinal liquid, and lyophilizing.

8. The preparation method of the drug for preventing or/and treating coronavirus infection according to claim 7, wherein the mass of the water is 10-15 times of the mass of the medicinal materials, the decocting times are 1-3 times, and the time length of each decocting is 0.8-1.2 hours.